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Introduction. Celiac plexus neurolysis is used in pain management of patients with advanced and unresectable pancreatic cancer.
We retrospectively analyzed eﬃcacyandsafetyofendoscopicultrasound-(EUS-)guidedceliacplexusneurolysisinpatientstreated
in our unit. Methods. Twenty nine subjects with unresectable pancreatic cancer and severe pain despite pharmacological treatment
underwent EUS-guided celiac plexus neurolysis with 98% ethanol. Patients scored their pain according to a 0–10 point scale and
wereinterviewed1-2weeksand2-3monthsaftertheprocedure.Results. Twentyﬁve(86%)patientsreportedimprovementintheir
pain at 1-2 weeks following the procedure. Of these, 7 (24%) reported substantial improvement (decrease in pain by more than
50%) and 4 (14%) complete disappearance of pain. Pain relief was still present in 76% of patients after 2-3 months. Treatment-
related side eﬀects included hypotonia in 1 patient, severe pain immediately postprocedure in 2 patients, and short episodes of
diarrhea in 3 patients. Conclusion. Endoscopic ultrasound- (EUS-) guided celiac plexus neurolysis is a safe and eﬀective treatment
of severe pain from advanced pancreatic cancer.
1.Introduction
Treatment of pain in patients with advanced pancreatic can-
cer is one of the most important goals of palliative care.
It is estimated that pain occurs in 80–85% of patients
with unresectable pancreatic tumors [1, 2]. Despite the im-
provedeﬀectivenessofpharmacotherapy,treatmentofsevere
pain from inoperable pancreatic cancer remains an impor-
tant clinical issue. Conventional drugs do not provide ade-
quate analgesia and many adverse eﬀects are also seen with
opioids. Therefore, interventional or surgical methods of
pain treatment are attractive alternatives in such patients [3,
4]. For example, celiac plexus neurolysis destroys the plexus
thatplaysacrucialroleintransmittingpainofpancreaticori-
gin. The procedure involves direct injection of a chemical
agent, a solution of alcohol or glycol, into the celiac plexus
ganglia [1–5].
Percutaneousceliacplexusneurolysiswasﬁrstperformed
by Kapisa in 1914. Since then, it has been performed by
many techniques for access, and with a variety of chemicals
[6].Percutaneousneurolysisunderradiologicguidanceisthe
most commonly applied. The needle is ﬁrst introduced into
the region of the celiac plexus under ﬂuoroscopic guidance.
A mixture of alcohol or phenol with the addition of contrast
medium is administered. A limitation of this method is the
lack of direct visualization of the celiac trunk, resulting in
only an approximation of location of the puncture site. As
a result, the risk of vascular or neurologic complications is
higher when accessed from the lumbar region. CT-guided
neurolysis is a modiﬁcation with similar limitations as ﬂu-
oroscopy [4].
Intraoperative celiac plexus neurolysis during surgery is
seldomly used because in most cases, the diagnosis of unre-
sectable pancreatic cancer is established without the need for2 Gastroenterology Research and Practice
laparotomy. Such patients usually require endoscopic stent-
ing of the biliary tree and adequate pain control [3].
Endoscopic ultrasound- (EUS-) guided celiac plexus
neurolysis was ﬁrst described by Wiersema in 1996 [7]. The
authors visualized the celiac plexus with EUS and then per-
formedneurolysisviathetransgastricroute,achievingresults
comparable to percutaneous neurolysis. In the following 10
years,theendoscopictechniquehasbeenacceptedasanalter-
native method of celiac plexus neurolysis, and is now applied
in many centers [8–21].
We aimed to assess the safety and eﬃcacy of EUS-guided
celiac plexus neurolysis for pain management in patients
withadvancedandunresectablepancreaticcancer.Thisisthe
ﬁrst reported experience with this technique in Poland.
2. Methods
Thirty two patients diagnosed with advanced and unresec-
table pancreatic adenocarcinoma were selected as candidates
for EUS-guided celiac plexus neurolysis. The indication in
all cases was severe abdominal pain requiring the use of opi-
oids. Neurolysis was not performed in 3 patients because of
the inability to visualize the celiac plexus with EUS due to
atypicalanatomy.Thus,betweenMay2008andMay2009,29
patientsultimatelyunderwentEUS-guidedceliacplexusneu-
rolysis. All procedures were performed by 2 gastroenterol-
ogists (A. Wiechowska-Kozłowska and P. Milkiewicz) with
extensive experience in EUS (both performed more than
1000 examinations). The linear type EUS endoscope (Olym-
pus GF-UCT 160-OL5) with “spray” needles (ECHO 20
CPN, Cook Ireland) was used in all cases.
Fourteen (48%) men and 15 (52%) women, mean age 62
(range33–81)years,underwenttheprocedure.Thediagnosis
of advanced and unresectable cancer of the pancreatic head
(n = 13; 45%), the head and body (n = 3, 10%), the body
(n = 9; 31%), and the tail of the pancreas (n = 4; 14%)
was made based on abdominal computed tomography and
EUS.Tumorswereconsideredunresectablewhendistantme-
tastases and/or locally advanced tumors were present (i.e.,
tumor inﬁltration of the celiac trunk, superior mesenteric
artery or vein, and the retroperitoneum and periaortic area).
Eighteen (56%) patients had advanced local disease and 14
(44%) were diagnosed with metastasis disease. Adenocarci-
nomaofthe pancreaswasconﬁrmedinallpatients withﬁne-
needle aspiration biopsy under percutaneous (n = 11) or en-
doscopic (n = 18) ultrasound guidance. 11 (38%) patients
underwent palliative chemotherapy with gemcitabine.
Contraindications to the procedure included coagulation
disorders (INR > 1.5), platelet count <50,000, or previous
disease and treatment of the upper gastrointestinal tract
that would make endoscopic access impossible. These con-
traindications were not present in included patients. After
discussing the principles of the procedure, its consequences,
the possibility of partial or no reduction of pain, and compli-
cations, informed consent was obtained in all patients.
The procedure was performed in the left lateral position
after intravenous administration of 2.5mg of midazolam.
Clinical parameters such as heart rate, blood pressure,
oxygen saturation, and ECG were routinely monitored dur-
ing theprocedure. Theantibiotics prophylactic wasnot used.
The ﬁrst stage was assessment of tumor location, conﬁrming
its advanced and unresectable stage (Figure 1). Anatomic
landmarks (celiac trunk and aorta visible from the lesser cur-
vature of the stomach) were visualized ﬁrst. The needle was
introduced directly into the celiac plexus and surrounding
area under direct visualization of the vessels with the Dop-
pler mode. The aspiration test was routinely performed
(2mL of saline followed by aspiration), in order to exclude
intravascular puncture. A small amount of analgesic (2mL
of 2% lidocaine) was administered, followed by injection
of 98% alcohol solution (Figure 2). This was performed
three times: twice on either side of the aorta and 1 directy
to the celiac plexus. Altogether, 3 punctures of the celiac
plexus were performed with the total application of 6mL of
lidocaine and 20mL of 98% alcohol. During alcohol injec-
tion, a typical hyperechogenic shadow was observed and
patients experienced exacerbation of pain in this region de-
spite administration of analgesia.
After the procedure, patients were observed for 24 hours,
with clinical evaluation and measurement of vital signs. 27
patients were discharged on the next day while 2 patients re-
mained in the hospital for 2 days due to exacerbating pain.
All the patients were instructed to attempt to gradually dis-
continue the use of pain medication. The assessment of
eﬃcacy and related morbidity was based upon a survey
carried out prior to the procedure; on day 1, 1-2 weeks,
and 2-3 months following the procedure. The eﬀectiveness
of treatment was assessed based on the 11-point pain scale
(0 points, no pain; 10 points, maximal pain). The reduction
or discontinuation of pain medication was also considered.
The incidence and types of complications were evaluated by
clinical evaluation during and after the procedure, and by
surveying all patients on the degree of pain, changes in bowel
movements, neurological disturbances, and other clinical
symptoms. Analysis was retrospective and was based on the
hospital and endoscopy suit charts.
3. Results
A na v e r a g ep a i ns c o r eo f7 . 9( r a n g e6 – 1 0 )w a so b s e r v e d
in all patients prior to the procedure, requiring the use of
nonsteroid anti-inﬂammatory drugs and narcotic analgesics.
One-two weeks following treatment, full pain resolution (0-
1 points) was observed in 4 (14%) patients, who completely
stoppedtakingpainmedications.Seven(24%)patientshada
reduction in pain by more than 50% while 9 (31%) patients
had a reduction in pain by 30–50%. In 5 (17%) patients,
a small improvement (reduction of pain by <30%) was
found. In 4 (14%) patients, pain remained unchanged. Two-
three months following the procedure, 4 patients died due
to disease progression. These included 1 patient in whom
neurolysis was fully eﬀective, 1 patient with pain reduction
by 30–50%, 1 patient with pain reduction of <30%, and 1 in
whom the procedure was ineﬀective. Subsequent assessment
(2-3 months postprocedure) was performed in 25 patients.
Two (8%) patients were pain free and 5 (20%) patients
maintained pain relief of more than 50%. Seven (28%)Gastroenterology Research and Practice 3
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Figure 1: Images of endoscopic ultrasound in advanced pancreatic cancer: (a) tumor invading the vasculature, (b) portal vein thrombosis
in advanced pancreatic cancer, (c) ﬁne-needle aspiration biopsy of the pancreatic tumor.
(a) (b)
Figure 2: Endoscopic ultrasound-guided celiac plexus neurolysis: (a) typical location of the plexus with the celiac trunk (arrow) at the aorta,
(b) puncture of the celiac plexus with administration of alcohol under endoscopic ultrasound guidance.
patients reported a 30–50% pain reduction while 5 (20%)
and 6 (24%) patients had slight (<3 0 % )o rn oi m p r o v e m e n t ,
respectively (Figure 3).
A short but signiﬁcant episode of hypotension requiring
intervention occurred in 1 patient immediately after pro-
cedure. This normalized after treatment with an i.v. saline.
Two patients reported a temporary but signiﬁcant increase
in pain immediately after procedure, requiring analgesics in
increasing doses during the hospital stay. Both patients were
discharged home after two days. One patient was pain free at
discharge and 1 had a signiﬁcant (>50%) reduction in pain.
Three patients reported an increased frequency of bowel
movements (4-5 stools daily) although no chronic diarrhea
was observed in any patient.
4. Discussion
Celiac plexus neurolysis for pain management has been used
for almost 100 years in patients with advanced abdominal
malignancy [6]. The procedure is performed either or
intraoperatively, with varying eﬃcacy. According to the
metaanalysis of 24 studies, including 1145 patients who
underwent the percutaneous technique (mostly from the
posterior approach), pain reduction was observed in 90%
and 70–90% of patients at 2 weeks and 3 months follow-
ing the procedure, respectively [4]. Patients who underwent
percutaneous neurolysis experienced signiﬁcant pain relief,
enabling reduction of analgesic doses and improved quality
of life [2, 14–16, 20]. However, serious neurological compli-
cations were observed in 2% of patients (paralysis, paresis,
paresthesia of the lower extremities, pneumothorax, pleural
empyema) [2, 4, 14, 16, 21]. Intraoperative abdominal or
thoracoscopic celiac plexus destruction by direct alcohol
injection or surgical transection of ganglia have been applied
with an eﬃcacy comparable to the percutaneous technique
[3].
The ideal procedure should preferably be highly eﬃca-
cious, with low complication rates, and the least invasive.
Proper visualization of the celiac plexus followed by precise
administration of proper pharmacological agents all appear4 Gastroenterology Research and Practice
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Figure 3: Eﬃcacy of endoscopic ultrasound-guided celiac plexus
neurolysis: (i) early outcome (1-2 weeks after treatment), (ii) late
outcome (2-3 months after treatment).
to be fundamental prerequisites for successful and safe
neurolysis. Alcohol ablation is approximately twice as eﬀec-
tive, compared with ablation using phenol [19]. Moreover,
alcohol ablation is not associated with mutagenesis [19].
The introduction of EUS in the 1980s for imaging ab-
dominal organs, including the pancreas, made it possible
to precisely visualize the celiac plexus. The application of
interventional endoscopy in the 1990s permitted the perfor-
mance of controlled biopsies, drainage, or injection of drugs
into tissues surrounding the stomach or duodenum under
ultrasonographic guidance. Such procedures were previously
performed surgically or percutaneously only.
Wiersema was pioneered celiac plexus neurolysis under
EUS guidance in 1996, demonstrating high eﬃcacy in pa-
tientswithadvancedabdominalmalignancy(signiﬁcantpain
reduction in 79–88%) with low morbidity [7]. Subsequent
studies conﬁrmed these ﬁndings, showing a short-term suc-
cess rate of 78%, which decreased to 30% after 12 weeks of
follow-up, in particular, when no chemotherapy was applied
[11].
In our study, the eﬀectiveness observed early following
treatment appeared lower, since signiﬁcant pain reduction
was reported in 69% of patients, while 31% had slight or
no improvement. Late response to treatment, assessed 2-3
months following the procedure, was signiﬁcant in a rela-
tively large (56%) number of patients.
Theinabilitytocompletelycontrolthepaininallpatients
as well as reduction of pain relief over time was observed
in several studies [5, 8–10, 13, 20]. The reason why alcohol
injection into the plexus did not completely eliminate pain
may be explained by pathologic studies of the plexus follow-
ing treatment [19]. Alcohol injection resulted in only partial
destruction, and degeneration and ﬁbrosis of nerve ﬁbers
and ganglia [19]. As a result, continued transmission of pain
stimuli is still possible, although reduced in most patients
[19]. The site of injection is also important and should
preferably be performed at the most complex, ganglia-rich
location within the celiac plexus. Bilateral injection (on both
sides of the plexus) is more eﬀective compared with single
injection in the center of the plexus [17]. In order to destroy
as many nerves and ganglia as possible, we routinely applied
the triple injection method to the center of the plexus and
bilaterally.Thisisdiﬀerent,comparedwithotherreportsthat
describe a single injection of a standard dose (20mL) of the
drug [11, 12, 16]. The prospective studies comparing dif-
ferent injection methods and applying diﬀerent types of
needleshaveapotentialtoexplaindiﬀerencesin eﬀectiveness
of this procedure. In view of its limited eﬃcacy, any ef-
forts towards its improvement appear justiﬁed, including
increasing the dosage and changing the mode of injection.
Repeated procedures may also be of value in some cases, as is
injection of steroids into the plexus in patients with chronic
pancreatitis.
Optimal timing for EUS-guided celiac plexus neurolysis
is controversial. As in our study, it may be applied in a very
advancedstageinpatientsrequiringnarcoticanalgesia.Some
authors,however, recommend the performanceof neurolysis
early in the course of disease, before pharmacotherapy with
opioids has even been started [1, 16, 17]. In such cases,
eﬃcacy and safety may be increased.
Our study shows that EUS-guided celiac plexus neuroly-
sis is associated with a very low risk of complications. There
was no signiﬁcant treatment-related morbidity observed in
any patients.
5. Conclusion
EUS-guided celiac plexus neurolysis is a safe and eﬀective
treatmentofseverepaininpatientswithadvancedpancreatic
cancer. It provides signiﬁcant short-term pain relief in
the majority of patients. However, its eﬃcacy is limited,
indicating the need for further studies aimed at improving
the method.
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